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Osteoprotegerin (OPG) and receptor activator of
nuclear factor kB (RANK) are members of the tumor
necrosis factor receptor (TNFR) superfamily that
regulate osteoclast formation and function by com-
peting for RANK ligand (RANKL). RANKL promotes
osteoclast development through RANK activation,
while OPG inhibits this process by sequestering
RANKL. For comparison, we solved crystal struc-
tures of RANKL with RANK and RANKL with OPG.
Complementary biochemical and functional studies
reveal that the monomeric cytokine-binding region
of OPG binds RANKL with 500-fold higher affinity
than RANK and inhibits RANKL-stimulated osteo-
clastogenesis 150 times more effectively, in part
because the binding cleft of RANKL makes unique
contacts with OPG. Several side chains as well as
the C-D and D-E loops of RANKL occupy different
orientations when bound to OPG versus RANK.
High affinity OPG binding requires a 90s loop Phe
residue that is mutated in juvenile Paget’s disease.
These results suggest cytokine plasticity may help
to fine-tune specific tumor necrosis factor (TNF)-
family cytokine/receptor pair selectivity.
INTRODUCTION
Normal skeletal mass reflects a balance between bone-forming
osteoblasts and bone-resorbing osteoclasts (Leibbrandt and
Penninger, 2009; Seeman, 2009; Zaidi, 2007). When the activity
of osteoclasts substantially supersedes that of osteoblasts,
patients develop osteoporosis, a condition characterized by
reduced bone mineral density. In contrast, osteopetrosis,
a condition of extremely dense bone, is the product of failed
osteoclast formation or function.
The osteoclast is a polykaryon of hematopoietic origin whose
differentiation from monocyte/macrophage precursors uniquely
requires oligomerization and activation of the cell-surface
receptor activator of nuclear factor kB (RANK) by the tumor
necrosis factor (TNF)-like cytokine RANK ligand (RANKL)
(Boyce and Xing, 2008; Kim et al., 2000; Kong et al., 1999;Structure 20, 1971–19Lacey et al., 1998; Leibbrandt and Penninger, 2008; Teitel-
baum, 2007; Yasuda et al., 1998). In fact, RANKL can be
thought of as both an osteoclast differentiation and activation
factor (Lacey et al., 1998). RANKL, in conjunction with macro-
phage colony-stimulating factor (M-CSF), is sufficient to
prompt bone marrow macrophage differentiation into bone-
resorbing osteoclasts in vitro. Importantly, RANKL and its
receptor RANK are required for osteoclastogenesis in vivo.
Both RANKL (Kong et al., 1999) and RANK-deficient mice
lack osteoclasts (Dougall et al., 1999; Li et al., 2000). The
discovery that the later stages of osteoclast differentiation are
blocked in mice that overexpress the decoy receptor, osteo-
protegerin (OPG) (Simonet et al., 1997), established that
RANK and OPG reciprocally regulate bone resorption. The clin-
ical relevance of this relationship is underscored by the fact
that many forms of osteoporosis are characterized by an
increase in the ratio of circulating RANKL/OPG (Jabbar et al.,
2011; Wasilewska et al., 2010; Xu et al., 2011). Manipulation
of this ratio forms the basis of present antiosteoporosis
therapy. Hence, an understanding of the different mechanisms
by which RANK and OPG recognize RANKL could prove useful
in designing better therapeutics.
The RANKL gene was identified by expression cloning
using OPG and RANK as probes (Anderson et al., 1997; Lacey
et al., 1998; Wong et al., 1997; Yasuda et al., 1998). In addition
to osteoclastogenesis, RANKL mediates lymph node for-
mation, establishment of the thymic microenvironment, T cell
growth, and dendritic-cell function. The cytokine also governs
expansion and activity of mammary glands during pregnancy
and lactation and regulation of female basal body tempera-
ture (Anderson et al., 1997; Bachmann et al., 1999; Dougall
et al., 1999; Fata et al., 2000; Hanada et al., 2009; Kong
et al., 1999).
RANKL is an 35 kDa type II transmembrane protein with a
short N-terminal intracellular tail and a C-terminal extracellular
region that contains a connecting stalk and receptor-binding
domain (Figure 1A). Membrane-bound RANKL activates
RANK to generate osteoclasts through cell-cell contact. In
states of inflammatory osteolysis, RANKL is also cleaved to
release a soluble, biologically active product (Schlo¨ndorff
et al., 2001). Like most TNF-family cytokines (Bodmer et al.,
2002), RANKL forms a homotrimer in solution. Hydrophobic
interactions at the core of the trimer drive monomer assembly
around a 3-fold axis of symmetry. The individual monomers
are composed entirely of b strands and loops connected in82, November 7, 2012 ª2012 Elsevier Ltd All rights reserved 1971
Figure 1. Schematic of the OPG, RANK, and
RANKL Proteins
(A) RANKL domain architecture. The extracellular
receptor-binding domain is encoded as the
C-terminal region. (B)RANKdomainarchitecture. In
RANK, the CRDs are followed by a transmembrane
domain (TM) and a cytoplasmic tail containing
TNFR-associated factor (TRAF)-binding motifs.
(C) OPG domain architecture. In OPG, the CRDs
are followed by two death domain-related regions
(DD) and a highly charged basic region.
(D) OPG/RANKL and RANK/RANKL complexes
in the context of cell membrane insertion. Arrows
indicate where proteins were truncated for crys-
tallographic studies.
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RANKL Binding by OPG and RANKa ‘‘jelly-roll’’ fold, with the two b sheets of each monomer stack-
ing as a sandwich (Lam et al., 2001). The sequence similarity
among TNF-like cytokines is largely confined to the 25%–
30% of internal residues responsible for trimer stability. As
each trimer assembles, loops at the edges of apposed mono-
mers form the sides of the receptor-binding clefts, the shape
of which determines receptor selectivity. For RANKL, the three
identical receptor-binding clefts are spaced equally around the
outside of the cytokine.
RANK, the cell surface signaling receptor, is expressed as an
67 kDa type I transmembrane protein consisting of four extra-
cellular cysteine-rich domains (CRDs) linked to a long C-terminal
intracellular region (Figure 1B). Like most members of the TNF-
receptor superfamily, the CRDs of RANK consist of pseudore-
peats, each approximately 40 residues in length, containing
between one and three disulfide bridges. These CRDs can be
further characterized as consisting of pairs of structurally
conserved modules distinguished by fold type and number of
disulfide bonds (Naismith and Sprang, 1998). Binding of RANKL
to the CRDs of RANK stimulates receptor trimerization (Fig-
ure 1D). Indeed, the 3-fold symmetry enforced by the cytokine/
receptor complex appears to be the stoichiometry of most1972 Structure 20, 1971–1982, November 7, 2012 ª2012 Elsevier Ltd All rights reservedTNF/TNF receptor (TNFR) superfamily
signaling interactions (Bodmer et al.,
2002; Hehlgans and Pfeffer, 2005; Locks-
ley et al., 2001). The RANK protein lacks
intrinsic enzymatic activity, but upon
trimerization recruits signaling adaptors
and other TNFR–associated factors that,
in turn, activate osteoclastogenic signal-
ing networks (Armstrong et al., 2002;
Wong et al., 1998).
OPG, the naturally occurring decoy
receptor for RANKL, is synthesized as
an 55 kDa monomer that self-associ-
ates to form a disulfide-linked homodimer
prior to secretion (Figure 1D). Like RANK,
the N-terminal half of OPG consists of
four CRDs that are necessary and suffi-
cient to inhibit osteoclast formation
(Yamaguchi et al., 1998) (Figure 1C). The
decoy receptor’s C-terminal half contains
a dimerization cassette, comprised of
two regions with similarity to cytoplasmicdeath domains, juxtaposed to a heparin-binding basic motif
and having cysteine as the penultimate residue. Dimer forma-
tion enhances the receptor’s avidity for RANKL, which is likely
central in the receptor’s ability to inhibit osteoclast formation
in vivo (Schneeweis et al., 2005).
OPG is secreted primarily by osteoblasts and marrow stromal
cells. By sequestering RANKL, OPG inhibits the RANKL/RANK
interaction, blunting the maturation and bone-degrading
capacity of osteoclasts. Although human mutations in OPG
are rare, loss of function severely affects bone growth. About
50 individuals worldwide have been identified with juvenile
Paget’s disease, an autosomal recessively inherited osteopathy
characterized by accelerated bone remodeling, low bone
mineral density, fractures, and progressive skeletal deformity.
The disease displays considerable phenotypic variation, the
severity of which correlates with specific mutations in the OPG
gene. The most affected individuals carry large homozygous
deletions of OPG or missense mutations in cysteine residues
predicted to cause major disruption of the RANKL binding
domain. Less affected individuals carry point mutations in the
CRDs thought to alter RANKL binding (Chong et al., 2003). The
physiologic role of OPG is not limited to the inhibition of bone
Table 1. Data Collection and Refinement Statistics
Data Set OPG-RANKL RANK-RANKL
Space group P63 P63
Unit cell
dimensions (A˚)
a = b = 109.8,
c = 78.8
a = b = 120.6,
c = 94.3
X-ray source ALS 4.2.2 Rigaku RUH3 CuKa
Wavelength (A˚) 0.9951 1.5418
Resolution range (A˚) 50.0–2.70 20.0–2.70
(Outer shell) (A˚) (2.79–2.70) (2.87–2.70)
Observations/unique 42,626/14,907 107,644/21,055
Completeness (%) 99.4 (99.9) 98.0 (90.2)
Reflections Rsym (%)
a 8.4 (56.3) 8.0 (53.7)
<I/sI> 10.6 (2.6) 13.9 (2.2)
<Redundancy> 2.9 5.9
Refinement Statisticsb
Protein atoms/solvent 2,280/95 2,574/81
(Outer shell) (A˚) (2.79–2.70) (2.77–2.70)
Rwork (%) 19.4 (25.7) 19.4 (25.7)
Rfree (%) 23.0 (29.2) 21.6 (35.2)
Ramachandran plot,
most favored/
additional (%)
94.0/5.6 96.2/3.8
RMSD bond length
(A˚/angles) ()
0.002/0.600 0.003/0.576
RMSD dihedral () 10.08 9.5
Advanced Light Source Beamline 4.2.2. See also Table S1.
aValues as defined in HKL2000.
bValues as defined in Phenix.
Figure 2. Comparison of the OPG/RANKL and RANK/RANKL
Complexes
(A) Lateral view. The RANKL trimer is illustrated as awhite surfacemodel, while
OPG (magenta) and RANK (green) are presented as ribbons. The approximate
position of each CRD is detailed (left). Disulfide bridges (yellow balls and sticks)
form the framework of each receptor. To compare the relative orientation of
RANK and OPG in the binding cleft, the cocomplex structures were aligned
by superposition of the RANKLs. Circles indicate the approximate locations of
various RANKL loops.
(B) Bottom-up view. Three OPG receptors are shown captured in three equally
spaced binding clefts around the surface of the RANKL trimer. A black triangle
marks the three-fold crystallographic axis of symmetry.
See also Tables S3 and S6.
Structure
RANKL Binding by OPG and RANKresorption. OPG also binds to and inactivates TNF-related
apoptosis-inducing ligand (TRAIL) (Emery et al., 1998), amember
of the TNF family that promotes immune cancer surveillance.
TRAIL also binds decoy receptors 1 (DcR1) and 2 (DcR2) that
fail to induce apoptosis due to a lack of functional death
domains.
The modular nature of TNF-receptor CRDs permits deter-
mination of accurate sequence alignments, even in the absence
of significant sequence conservation. Accurate structural
modeling of TNF receptors has proven difficult. Further, without
structural data, predicting the binding selectivity of specific TNF
receptors is problematic, due to uncertainties in the positions
and orientations of successive modules as well as the conforma-
tions of divergent loops. This is particularly relevant for the
RANKL system. The inherent complexity (RANKL binding both
OPG and RANK and TRAIL binding OPG, death receptor 4
[DR4], DR5, DcR1, and DcR2) raises basic questions about
binding modes and selectivity that can only be answered at the
molecular level.
The capacity of OPG to dampen osteolysis makes it and
related molecules candidate antiosteoporosis therapeutic
agents. With this in mind, we determined crystallographic struc-
tures for RANK and OPG in association with RANKL. The two
TNF receptors compete for the same binding cleft, but for
different biological purposes: RANK as a signaling receptor
and OPG as a decoy receptor. This exercise provides structural
insight into the determinants that support the decoy function:Structure 20, 1971–19information that may prove important for the design of improved
antiosteoporosis drugs.
RESULTS
Structure Determinations
To compare the interactions of OPG and RANK with RANKL, we
prepared murine receptor/cytokine complexes for structural
analysis. Both pairs formed crystals in space group P63 (Table
1). Although the packing was similar, the unit cell of the OPG/
RANKL crystal was smaller than that of its RANK/RANKL coun-
terpart. Native diffraction data for the OPG/RANKL complex
were collected to 2.70 A˚ resolution. Phasing was accomplished
by a combination of molecular replacement based on our
structural model of the cytokine (Lam et al., 2001) and multi-
wavelength anomalous diffraction (MAD) using selenomethio-
nine-labeled RANKL (Table S1 available online). Structural
refinement yielded a final model with an Rwork of 20.2% and Rfree
of 24.0% and with root-mean-square deviations (rmsds) from
ideal values of 0.003 A˚ for bond lengths and 0.650 for bond
angles (Table 1). In the OPG/RANKL crystal structure, the first
eight N-terminal residues of OPG are disordered, as is the last
half of CRD4. The crystallographic asymmetric unit consists of
one molecule of OPG (residues 9–141) and one monomer of
RANKL (residues 162–315). A 3:3 complex (or heterohexamer)
becomes apparent upon application of the 3-fold crystallo-
graphic symmetry (Figure 2). Each OPG-binding cleft incorpo-
rates two neighboring RANKL monomers: one contributing the
A0-A00 loop side and the other the D-E loop side of the cleft
(Figure S1).
The RANK/RANKL complex was crystallized, diffraction
data collected to 2.7 A˚ resolution, and the structure phased by82, November 7, 2012 ª2012 Elsevier Ltd All rights reserved 1973
Figure 3. Comparison of OPG and RANK Contact Residues at the RANKL Interface
(A) Structure-based sequence alignment of cytokine-binding regions. The mouse OPG (mOPG) sequence numbering, as counted from the amino-terminus of
the mature protein, is given above the alignment. The mouse RANK numbering is given under the alignment. Individual amino acids interacting with the cytokine
(%4 A˚) are boxed and colored according to contact distance using the scale shown in panel B. The shortest distance between any atom interface pair determines
the color for the entire residue. The CXC hinge region linking CRDs 2 and 3 (OPG residues 84–86) is boxed in black with a gray background. Red lines connect
disulfide-bonded cysteine residues. The positions of the ‘‘50s’’ and ‘‘90s’’ loops, implicated in controlling the ligand-binding specificity of TNFR family members,
are shown under the alignment.
(B) Surface representation of OPG, RANK, and RANKL. Each receptor/cytokine complex has been opened like a book to reveal the contacting surfaces. Key
interacting residues are delineated and are colored by distance using the scale shown. Important RANKL loop regions are circled.
See also Tables S2 and S4.
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RANKL Binding by OPG and RANKmolecular replacement using our RANKL model (Lam et al.,
2001). The RANK fragment contained only the ligand-binding
ectodomain (residues 5–168). Structural refinement yielded
a Rwork of 18.8% and Rfree of 21.6% with an rmsd from ideal
values of 0.002 A˚ for bond lengths and 0.576 for bond angles
(Table 1). Satisfactory density was observed for RANK,
excluding a few residues at the N-terminus. Similar to the
OPG/RANKL crystal, the RANK/RANKL crystal also contains
one subunit of receptor and cytokine in each asymmetric unit.
RANK Is More Elongated than OPG
Only 34% of the residues at structurally equivalent positions
in OPG and RANK are identical, falling to 26% if only noncys-
teine positions are considered (Table S2). Despite the low
sequence identity throughout the cytokine-binding regions,
OPG and RANK share a similar structural framework. Super-1974 Structure 20, 1971–1982, November 7, 2012 ª2012 Elsevier Ltdposition of the individual CRDs reveals substantial fold simi-
larity, with rmsds of equivalent Ca varying from 0.9 to 1.5 A˚
(Table S3A).
A flexible articulation point separating CRD2 and CRD3 is a
common feature of TNFR family members. This ‘‘hinge,’’ identifi-
able by the characteristic CXC motif (Mongkolsapaya et al.,
1999), enables TNFRs to adopt distinct orientations in different
solvent conditions. The hinge conformation differs in the OPG
and RANK cocomplexes, and as a result, OPG appears to be
more bowed than RANK when bound to RANKL. This is in part
due to a two-residue deletion in the CRD2 region of OPG (Fig-
ure 3A). The shorter OPG CRD2 loop combines with sequence
disparity at the CRD2/CRD3 interface to shift the relative posi-
tion of CRD3. Accordingly, a twist of 17 and a swing of 32
pivoting about the CXC hinge would place the OPG CRD3 onto
the RANK CRD3 (Figure 2A).All rights reserved
Figure 4. Conformational Effects of C-D
and D-E Loop Rearrangements
(A) Alignment of RANKL from the OPG/RANKL
and RANK/RANKL complexes. Only two RANKL
monomers are visualized from each complex. The
RANKL strands are labeled A-H with the protein
terminimarked ‘‘n’’ and ‘‘c.’’ Portions of theRANKL
structure with Ca rmsds <2 SD from the mean are
white,while thosewithR2SDvariance are colored
(OPG/RANKL, magenta; RANK/RANKL, green).
(B) Lateral view of OPG CRDs 2 and 3 shown
against one half of the receptor-binding cleft
formed by the A0-A00 loop side RANKL monomer. A
small inset contains the OPG/RANKL complex
boxed to show the region selected for magnifi-
cation. The RANKL C-D loop is orange. OPG is
again magenta in color with yellow disulfides.
Hydrogen bonds appear as thin cyan lines. The
atoms involved in nonbonded contacts are en-
closed in a blue transparent surface generated
using Ligplot+ at the default values (Laskowski
and Swindells, 2011). The b2-b3 strands comprise
the CRD3 projection, often referred to as the ‘‘90s
loop.’’ The right panel shows a close-up view of
the CRD3 projection looking straight into the cleft
with important residues labeled.
(C) Lateral view of RANK CRDs 2 and 3 in the
binding cleft of RANKL in the same orientation as
in (B). RANK is shown in green. The atoms
involved in nonbonded contacts are enclosed in
a pink transparent surface. Again, the right panel
shows a close up view of the CRD3 projection
looking straight into the binding cleft.
See also Figures S1–S3.
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RANKL Binding by OPG and RANKLike other TNFR family members, OPG and RANK use CRD2
and CRD3 to bind cytokine, with CRD2 contributing approxi-
mately 60% and CRD3 about 40% of the surface area buried
upon RANKL binding by either receptor (Table S3B). The specific
residues contacting RANKL are highlighted in the structure-
based sequence alignment (Figure 3A). The CRD module classi-
fications are detailed above the sequence according to the
method of Naismith (Naismith and Sprang, 1998), wherein A or
B indicates fold type and X1 and X2 denote number of amino
acids between folds. RANK buries 12% more total surface
area than does the OPG decoy receptor. Interestingly, OPG
and RANK divide the buried surface area differently between
the two sides of the binding cleft (Figures 3B). RANK buriesStructure 20, 1971–1982, November 7, 2012 ªmore surface area against the A0-A00
loop side of the cleft than against the D-
E loop side. In contrast, OPG uses the
D-E loop side more and the A0-A00 loop
side less than does RANK.
Different Conformations of RANKL
Engage OPG and RANK
While both receptors bind at the interface
formed between two RANKL monomers,
there are distinct differences in the resi-
dues of RANKL that are utilized by OPG
versus RANK (Figure 3B). Additionally,the shape of the RANKL-binding cleft recognized by OPG is
different than that recognized by RANK. Despite this difference,
the shape complementarity values calculated for each receptor/
cytokine interface are similar (RANK, Sc = 0.656 and OPG, Sc =
0.675), suggesting that the receptors have evolved to fit their
respective binding clefts equally well.
Although the conformation of RANKL in the RANK/RANKL
complex is strikingly similar to that of the cytokine alone (Ito
et al., 2002; Lam et al., 2001), the RANKL D-E loop residues
246–250 and C-D loop residues 225–234 are rearranged
apparently to accommodate OPG binding (Figure 4A). The D-E
loop is not well ordered in the RANK/RANKL structure. It
adopts a conformation closely resembling the D-E loop seen in2012 Elsevier Ltd All rights reserved 1975
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RANKL Binding by OPG and RANKthe unliganded cytokine and likewise displays high B-factor
values, suggesting that this loop is mobile. In the OPG complex,
the D-E loop adopts a well-defined conformation, where it
makes unique contacts with the first half of OPG CRD2.
The C-D loop rearrangement is more complicated. The OPG/
RANKL interaction requires a cascade of side chain movements
at the base of the cytokine receptor-binding cleft (compare
Figures 4B and 4C). The rotamer adopted by OPG-bound
RANKLF269 leaves the phenyl ring turned toward the C-D loop.
Nearby, the imidazole ring of RANKLH224 is turned away from
the receptor. Additionally, the side chain carboxylic acid group
of RANKLE225 is rotated approximately 110 away from the
receptor, shifting the backbone of the C-D loop. The loop pivots
at RANKLE225 and RANKLY234. As a result of these rearrange-
ments, the side chain of RANKLY234 is swung approximately
90 out of the binding site to release its end of the C-D loop.
These alterations create a novel hydrophobic pocket at the
base of the binding cleft that accepts the phenyl ring of
OPGF96. Hence, a tight fit of OPG with RANKL does not appear
possible without significant shifts in the positions of side chains
within the receptor-binding cleft and displacement of the C-D
loop (Figure S2).
The OPG/RANKL Interface Is More Hydrophobic than
That of RANK/RANKL
The contacts between OPG CRD2 and the D-E loop of RANKL
are largely hydrophobic, with additional CRD2 contacts forming
an elongated hydrophobic patch buried deep in the binding cleft
along the E strand (Figure S3A). The key OPG-binding element
is contained in the CRD3 module. The b2 and b3 strands of
CRD3 form a tight loop capped by OPGF96 that juts into the
binding site (Figure 4B). This projection corresponds to the
‘‘90s’’ loop, a region that controls the ligand-binding specificity
of several TNF receptor family members (Hymowitz et al.,
1999). Virtually every residue of this b2-b3 projection interacts
with RANKL (Table S4A). The phenyl group of OPGF96 is involved
in a pi-stacking interaction with the phenyl group of RANKLF269
at the beginning of the F strand. This interaction is possible
because the rotamer of RANKLF269 creates a deep pocket that
accepts the phenyl ring of OPGF96. Consequently, the C-D
loop residues of RANKL converge around OPGF96 to form a
large, contiguous cluster of hydrophobic interactions with the
OPG b2-b3 projection.
The hydrophobic contacts between RANK and RANKL are
more isolated than those of OPG and more distributed around
the binding interface (Figure S3B). The CRD2 module of RANK
contains fewer residues juxtaposed to the D-E side of the RANKL
cleft than does OPG, and thus the overall number of contact
sites, in this region, are less. RANKE54 generates a salt bridge
with RANKLK247 in the D-E loop and RANKD55 does so with
RANKLR283 in the F-G loop. On the other side of the cleft, the
CRD2 module of RANK contacts the A0-A00 loop (Figure 4C).
Again, whereas the OPG/RANKL interactions are primarily
hydrophobic, those of RANK/RANKL are generally charge
driven, including two salt bridges (RANKD64 to RANKLR222 and
RANKK67 to RANKLD299) as well as a hydrogen bond (RANKK56
to RANKLG191).
The RANK CRD3 b2-b3 strand also forms a tight loop and, like
OPG, virtually every residue in the RANK b2-b3 projection inter-1976 Structure 20, 1971–1982, November 7, 2012 ª2012 Elsevier Ltdacts with RANKL. The structural position analogous to OPGF96
is occupied in RANK by a unique disulfide bond (C95-C97).
However, unlike OPGF96, this disulfide fails to make strong
hydrophobic contacts with RANKL. Instead, the RANK b2-b3
projection forms several hydrogen bonds, including RANKC98
to RANKLH224 and RANKY89 to RANKLE225 in the C-D loop, as
well as RANKS93 to RANKLK180 in the A-A0 loop. The interaction
of RANKwith the RANKL A-A0 loop also includes two salt bridges
(RANKD94 to RANKLH179 and RANKE96 to RANKLK180), again
highlighting the ionic nature of the RANK/RANKL interface
(a complete list of interface contacts are given in Table S4A for
OPG/RANKL and S4B for RANK/RANKL).
To determine the relative hydrophobicity of the OPG/RANKL
and RANK/RANKL interfaces, we utilized the protein interfaces,
surfaces, and assemblies (PISA) server (Krissinel and Henrick,
2007). PISA assigns a P-value by comparing randomly selected
surface atoms to those in the contact area. A P-value greater
than 0.5 indicates the contact surface is more hydrophilic than
one randomly generated, whereas a P-value less than 0.5 indi-
cates greater hydrophobicity.
The P-values of the A0-A00 and D-E loop sides of the RANK/
RANKL interface are 0.701 and 0.925, respectively. These data
indicate the surface of RANKL buried by RANK is hydrophilic.
In contrast, the respective P-values of the OPG/RANKL interface
are 0.211 and 0.367 for the A0-A00 and D-E loop sides. Thus, the
surface of RANKL buried by OPG is, in contrast, hydrophobic.
While this difference partly reflects the distinct footprints of
RANK and OPG on RANKL, it is primarily due to a change in
the chemical nature of the RANKL-binding groove caused by
the side-chain shifts and loop rearrangements.
OPG/RANKL Is More Stable than RANK/RANKL
We determined single-site affinities for RANKL binding to
monomeric CRD-spanning regions from OPG and RANK
using surface plasmon resonance (SPR). In this circumstance,
RANKL (cleaved and purified to remove the glutathione
S-transferase [GST]-tag) was coupled to a CM5 sensor chip
using N-hydroxysuccinimide/1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride chemistry. Monomeric constructs
spanning the cytokine-binding regions of RANK, OPG, or
OPG variants were flowed over the chip surface. The binding
appeared both specific and saturable. By Scatchard analysis,
an equilibrium affinity of KD, equilibrium = 2.09 mM was obtained
for the interaction between monomeric RANK and RANKL (Fig-
ure 5B). The monomeric CRDs of OPG bound with significantly
higher affinity than RANK (for OPG, KD, equilibrium = 4.24 nM).
Similar single-site binding affinities were obtained using
biolayer interferometry on an octet red system (Table S5).
SPR kinetic analysis indicates that OPG exhibits an approxi-
mately 30-fold faster on-rate and an approximately 20-fold
slower off-rate than RANK (Figure 5A). The higher affinity and,
in particular, the longer off-rate of the OPG fragment are
consistent with the function of the intact protein as a decoy
receptor.
High-Affinity RANKL Binding Requires OPGF96
The equivalent position of OPGF96 in humans (OPGF117) is
mutated to leucine in a subset of families with juvenile Paget’s
disease (Chong et al., 2003), a disorder of accelerated boneAll rights reserved
Figure 5. Comparison of the Affinity for RANKL of Monomeric Cytokine-Binding Regions from OPG, OPGF96A, OPGF96L, and RANK
(A) Binding curves for the interaction of monomeric truncated receptor (CRDs 1 through 4) with RANKL obtained from SPR data using a Biacore T100. Soluble
RANKL was coupled directly to a CM5 chip and various concentrations of soluble OPG, OPGF96A, OPGF96L, and RANK receptor CRDs were injected through the
flow cell at the concentrations listed on the sensorgrams. A summary table of the affinity constants determined by kinetic analysis is given under each sen-
sorgram, ka(1/Ms), kd(1/s), and KD kinetic(M). The values in each table represent the average of three independent experiments and the standard deviation. The
RANK CRD curves were fit simultaneously to determine kd/ka using a 1:1 (Langmuir) binding model. The OPG CRD data were fit using a two-state reaction
(binding with conformational change) model. The fits are included on each set of sensorgrams as a thinner set of curves. A cartoon of the experimental setup is
given below each set of binding curves.
(B) Saturation curves and Scatchard plots for the experiments in (A) at equilibrium. Scatchard analysis of the cytokine-receptor fragment interaction yields the
affinity at steady state, KD equilibrium (M). The values reported for each are from the representative experiment shown with the standard deviation determined from
three individual experiments.
See also Tables S5 and S7.
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RANKL Binding by OPG and RANKresorption due to enhanced osteoclastogenesis. This phenotype
is consistent with OPG dysfunction (Bucay et al., 1998; Mizuno
et al., 1998). FoldX analysis (Schymkowitz et al., 2005) of the
interface suggested F96 as the most energetically important
residue of OPG for RANKL binding. Based on the disease asso-
ciation, and the apparent importance of OPGF96 for RANKL
binding, we constructed an OPGF96A mutant to determine
whether complete removal of the hydrophobic, pi-stacking
head group at this position would yield a dramatic decrease in
affinity. Indeed, this single substitution diminished the affinity
for RANKL by approximately 60-fold (Figure 5). The dissociation
rate of the OPGF96A CRDs from RANKL was essentially the same
as thewild-typeOPGCRDs. However the on-rate of theOPGF96A
CRDs was approximately 30-fold slower than wild-type (Fig-
ure 5A). Clearly, the aromatic ring of OPGF96 is important for
rapid high-affinity binding. Interestingly, the juvenile Paget’s
disease mutation, OPGF96L, decreased binding of the CRD-
spanning fragment to RANKL even further by approximately
2,900-fold compared to wild-type. The disease mutant CRDsStructure 20, 1971–19displayed about a 270-fold slower on-rate and a 5-fold faster
off-rate. Indeed, the OPGF96L CRDs bound RANKL with approx-
imately a 6-fold lower single-site affinity than did monomeric
RANK.
To complement our binding analysis, we tested the ability of
the monomeric CRD-spanning fragments from wild-type OPG,
OPGF96A, OPGF96L, and RANK to inhibit osteoclastogenesis
in vitro. Bonemarrowmacrophageswere culturedwith osteoclas-
togenic amounts of M-CSF and RANKL in the presence of
increasing concentrations of soluble monomeric RANK, OPG,
OPGF96A, or OPGF96L CRD-spanning fragments. Binding of
soluble receptor fragments to RANKL is expected to block its
association with RANK on the cell surface and thereby prevent
precursor cells from differentiating into mature osteoclasts. After
five days, the cells were stained for tartrate-resistant acid phos-
phatase (TRAP) activity and osteoclasts counted (Figure 6). No
osteoclasts developed in the absence of RANKL. Although all
the receptor CRD regions were ultimately inhibitory, the wild-type
OPG CRDs were nearly 20-fold more effective than OPGF96A,82, November 7, 2012 ª2012 Elsevier Ltd All rights reserved 1977
Figure 6. Effect of Soluble Monomeric OPG, OPGF96A, OPGF96L, or
RANK Receptor Fragments on Osteoclast Formation
Bone marrow macrophages were cultured in M-CSF ± RANKL with increasing
concentrations of OPG, OPGF96A, OPGF96L, or RANK-truncated receptor
regions (CRDs 1 through 4) as soluble inhibitors. Also included was a set of
control wells without any monomeric soluble receptor fragment (CONT). On
day 5, the cells were stained for TRAP activity and osteoclasts were counted.
Data represent the mean ± the standard deviation of four well replicates for
each point and are representative of three individual experiments.
Structure
RANKL Binding by OPG and RANK200-foldmore thanOPGF96L, and150-foldmore thanRANK.Thus,
the pathological mutation, OPGF96L, renders the decoy receptor
incapable of potent RANK/RANKL signaling blockade, explaining
the osteolytic phenotype in patients with juvenile Paget’s disease.
DISCUSSION
Our comparison of OPG and RANK, in complex with RANKL,
reveals structural features that dictate the biological properties
of each. Although they differ in primary sequence and number
of disulfide bonds, the cytokine-binding domains of OPG and
RANK are similar in fold. However, despite the topological
resemblance, the receptors adopt different orientations within
the RANKL-binding groove. Both contact RANKL via their
CRDs 2 and 3. Yet RANK is more elongated than OPG, in part
because the decoy receptor bends sharply around the hinge
region joining CRDs 2 and 3. It is possible that this bend is
required for the cytokine-binding regions of OPG to reach the
dimerization domains, so as to occupy two RANKL binding sites
simultaneously.
The OPG/RANKL and RANK/RANKL interactions diverge in
other ways. RANK distributes its contacts evenly around the
RANKL binding site. In contrast, the contacts made by the first
half of OPG CRD2 are limited to part of the E-strand and D-E
loop region of RANKL, avoiding almost completely the A0-A00
loop region of the binding cleft. Further, the majority of OPG1978 Structure 20, 1971–1982, November 7, 2012 ª2012 Elsevier LtdCRD3 contacts concentrate around the deeply buried OPGF96,
which we have shown is required for rapid high-affinity binding.
Even when RANK and OPG interact with the same RANKL resi-
dues, they often do so differently. For example, RANKLH224
extends out of the binding site to form a hydrophobic interaction
with OPGL69. In the analogous region, RANKLH224 forms
a hydrogen bond with the backbone carbonyl oxygen of
RANKC98. Regardless, there are some shared contacts between
the signaling and decoy receptors; for example, RANKLQ236
contacts backbone atoms in CRD3 of both OPG and RANK.
RANKLQ236 makes nonbonded contacts with OPGF96 and a
hydrogen bond to the backbond oxygen of RANKC95. It is worth
noting that the structurally equivalent residue in TRAIL, Q205,
makes contact with DR5, and alanine substitution of Q205
decreases the apoptotic activity of TRAIL by approximately
690-fold (Hymowitz et al., 2000). This analysis underscores the
importance of structural information to guide residue-specific
targeting of the interface for therapeutic purposes.
It is still unclear what role avidity plays in the competition for
RANKL. In vivo, intact full-length OPG likely binds as a dimer,
forming a bivalent interaction with RANKL at the cell surface,
either to a single trimer or possibly by cross-linking adjacent
trimers. In addition, OPG may recognize the RANKL cytokine
shed in solution. The extra avidity afforded by OPG dimerization
likely contributes to its role as a decoy receptor (Schneeweis
et al., 2005). In contrast, RANK is constrained to move in the
plane of the cell membrane, where oligomerization of three
RANK receptors by RANKL is likely required for signal induction.
The ability of bivalent OPG to block assembly of the trivalent
RANK/RANKL complex probably depends on its higher intrinsic
affinity, which appears from our monovalent binding data to
be driven by both a faster association rate and a slower dissoci-
ation rate. Our findings that monomeric OPG CRDs alone are
roughly 150-fold more potent at inhibiting osteoclastogenesis
than their RANK counterparts bolster this concept.
OPG interacts with another TNF family cytokine, TRAIL (Wiley
et al., 1995). TRAIL induces tumor apoptosis upon binding to
DR4 and DR5, two cell-surface TNFR-family members whose
cytoplasmic regions contain death domains (Baetu and Hiscott,
2002; Degli-Esposti, 1999). Although the relative affinity may
be weak (Truneh et al., 2000), TRAIL sequestration has been
argued to be a potentially negative consequence of therapeutic
treatment with OPG (Reid and Holen, 2009; Zauli et al., 2009).
Our OPG/RANKL structure, by providing atomic-level detail of
the decoy receptor complex, may aid in the engineering of
OPG variants incapable of TRAIL binding that could mitigate
these concerns.
The only other secreted decoy TNF receptor in humans is
DcR3. By sequence and structure, OPG appears more similar
to DcR3 than to any other TNFR family member. Both receptors
contain four CRDs, with the CRD3s two residues shorter than
many other TNF-family receptors, including RANK. DcR3
neutralizes three TNF-like ligands: TNF-like ligand 1A (TL1A),
Fas ligand (FasL), and LIGHT. The cocomplex structure of
DcR3/TL1A revealed that the CRD3 of DcR3 contributes little
to TL1A binding specificity (Zhan et al., 2011). These authors
suggest, by analogy, that the shorter OPG CRD3 might
contribute less to RANKL binding than the longer RANK CRD3.
However, our data establish that the CRD3s of RANK and OPGAll rights reserved
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buried upon RANKL binding (40% by both receptors). Further,
our mutagenesis experiments demonstrate that the CRD3 of
OPG contains a major determinant for RANKL binding (residue
F96). Whether the CRD3 of DcR3 functions in a more conven-
tional manner when binding FasL or LIGHT is unknown.
Two groups have reported X-ray determination of the RANK/
RANKL complex (Liu et al., 2010; Ta et al., 2010) (see Table S6
for a comparison of the rmsds between domains and the CXC
hinge angles observed in each structure). Our RANK/RANKL
structure most closely resembles 3ME2, and both models
include a sodium ion at the CRD3/CRD4 domain junction, which
has been proposed to stabilize the interface (Liu et al., 2010). The
evidence for the sodium ion in our model is based on several
factors; the proximity of the ion to four main chain oxygen atoms,
the octahedral configuration of the coordination sphere, the
expected distance between the ion and its coordinating atoms,
the good match between the B-factors of the ion and its coordi-
nating atoms, and the presence of sodium in the crystallization
conditions.
Based on an alignment ofmodules thatmake up theCRD2 and
CRD3 domains of RANK and OPG, Liu et al. predicted a model
for OPG/RANKL binding. Our efforts, however, provide unfore-
seen details of the RANKL/OPG interaction. We discovered
a large shift of the OPG CRD2 away from the RANKL A0-A00
loop, disagreeing with modeling predicting that OPGY61 and
RANKLY187 comprise a ring-stacking interaction. Our structural
analysis reveals these residues to be separated by more than
5 A˚. Despite the lack of contact with the RANKL A0-A00 loop,
CRD2 engagement of the RANKL D-E loop represents a major
binding element for OPG. Our structure suggests that the OPG
CRD2 could be engineered to include RANKL A0-A00 loop
contacts and thereby enhance binding affinity.
The OPG CRDs bind RANKL with an approximately 500-fold
higher single-site affinity than the RANK CRDs, attributable to
both a faster on-rate and a slower off-rate. Surprisingly, RANKL
buries less surface area and makes fewer salt bridges and
hydrogen bonds with OPG compared to RANK. The slower off-
rate is probably a reflection of the more hydrophobic nature of
the OPG binding cleft. The rearrangement of RANKL C-D loop
residues, to form the OPGF96 binding pocket, dictates partner
predilection, as evidenced by the decreased affinity of OPGF96A
and OPGF96L for RANKL. Further, the key mouse and human
residues involved in the RANKL C-D loop rearrangement are
conserved in man. OPGF96 corresponds to human OPGF117,
a residue mutated in a subset of patients with juvenile Paget’s
disease, a disorder of accelerated bone resorption. Furthermore,
we expressed recombinant wild-type OPG, OPGF96A, and
OPGF96L proteins in mammalian cells. Thus, the humanmutation
OPGF117L likely yields correctly folded protein that does not
function efficiently as a decoy receptor. (For a list of known
human disease causing mutations that occur at the RANK/
RANKL or OPG/RANKL interface and structure-based predic-
tions of their effects, see Table S7).
Our observation is that conformational changes in the RANKL-
binding cleft permit preferential recognition of OPG. Previous
studies established sequence diversity, amino acid insertions,
receptor flexibility, and receptor placement as determinants of
receptor/ligand selectivity in the TNF superfamily. The modifiedStructure 20, 1971–19shape and chemical nature of RANKL’s binding groove, in
response to OPG association, provides the first example
wherein realignment of residues within the receptor binding
site results in a shift to a higher-affinity conformation. Our crys-
tallographic efforts demonstrate that plasticity of the receptor-
binding cleft may be an additional feature regulating TNF/TNFR
specificity.
EXPERIMENTAL PROCEDURES
Expression and Purification of OPG, RANK, and RANKL
The CRDs of OPG (mouse strain C57BL/6) were expressed in High Five insect
cells (Invitrogen Life Technologies) using a baculovirus expression system.
A complementary DNA fragment encoding the N-terminal four CRDs immedi-
ately following the signal sequence of OPG (residues 22–197 of NCBI
Reference Sequence accession NP_032790) was inserted into a modified
baculovirus shuttle vector such that the OPG sequence was located down-
stream of a bee-melittin-derived signal peptide followed by a thrombin
protease cleavage site and a 6-His tag. Recombinant baculovirus was gener-
ated by Cellfectin (Invitrogen Life Technologies)-mediated cotransfection
of the transfer plasmid with Flashbac genomic DNA (Oxford Expression Tech-
nologies) into SF9 cells. Soluble OPG protein was recovered from the super-
natants of infected High Five cells by Ni(II)-nitrilotriacetic acid-coupled affinity
matrix (Ni-NTA) chromatography, cut with thrombin, and then purified by gel
filtration chromatography. The purified protein was stored at 4C for use in
crystallization in buffer consisting of 25 mM 4-(2-hydroxyethyl)-1-piperazinee-
thanesulfonic acid (HEPES) (pH 7.5), 20 mM sodium chloride, and 0.01%
sodium azide. The extracellular cytokine-binding domain of mouse RANK
was also produced in High Five insect cells. The transfer vector encoded the
endogenous signal peptide of RANK and all four CRDs (residues 1–198 of
NCBI Reference Sequence accession NP_033425) fused through a thrombin
cleavage site to a BirA biotin-ligase recognition site and ending in a 6-His
tag. Recombinant viral DNA was generated by site-specific transposition of
the transfer plasmid onto a baculovirus bacmid in DH10bac E. coli cells
(Invitrogen Life Technologies). DNA from the bacmid was transfected into
SF9 cells to produce recombinant virus particles and the RANK protein recov-
ered from infected cell supernatants by Ni-NTA chromatography. Alternately,
6HIS-tagged OPG protein (residues 22–191 of NCBI Reference Sequence
accession NP_032790) was recovered from supernatants of transiently trans-
fected HEK293F cells (Invitrogen Life Technologies). A construct encoding
the bee-melittin signal peptide, the OPG fragment, and a 6His tag was inserted
downstreamof the CMV promoter in the IRES-GFP expression vector pFM-1.2
(a gift of Dr. Filippo Mancia). The mammalian-expressed OPG was used
for binding studies, because it more closely matched the RANK protein in
length.
Recombinant mouse RANKL (residues 162–316 of NCBI Reference
Sequence NP_035743) was expressed as a soluble GST fusion protein in
E. coli strain BL21-CodonPlus (DE3)-RIL cells (Agilent Technologies), as
described previously (Lam et al., 2001). The GST-RANKL fusion protein was
captured on Glutathione Sepharose and cleaved with PreScission Protease
to release the RANKL ectodomain. The RANKL trimer was purified by gel
filtration chromatography. Fractions containing monodispersed protein were
pooled and kept at 4C in sizing buffer consisting of 25 mM HEPES (pH 7.5),
150 mM sodium chloride, and 0.01% sodium azide. Selenomethionine label-
ing of RANKL was achieved by feedback inhibition of methionine biosynthesis
prior to induction. In brief, a fresh colony containing the expression plasmid
in BL21-CodonPlus (DE3)-RIL cells was seeded into 10 ml of Luria broth con-
taining 100 mg/ml carbenicillin at 37Cwith shaking. When an OD600 of 0.6 was
reached, the 10ml starter culture was used to inoculate 1,000ml of methionine
deficient medium (Athena Enzyme Systems) at 30C in a 2-l Erlenmeyer flask
(1:100 dilution). When the density again reached OD600 of 0.6, 0.5 g feedback
inhibition stock (made by combining the following amino acids: 0.1 g of lysine,
0.1 g threonine, 0.1 g phenylalanine, 0.05 g leucine, 0.05 g isoleucine, 0.05 g
valine, and 0.05 g L-selenomethionine) was added to the culture. After
15 min, protein expression was induced by addition of 0.1 mM isopropyl
b-D-1-thiogalactopyranoside. The temperature was reduced to 25C and
the culture left for 16 hr before harvest.82, November 7, 2012 ª2012 Elsevier Ltd All rights reserved 1979
Structure
RANKL Binding by OPG and RANKCrystallization Conditions
To characterize the OPG-RANKL binding interface, we purified the N-terminal
ligand-binding fragment of OPG (CRDs 1 through 4) and mixed it with soluble
RANKL trimer to form homogeneous complexes having a subunit ratio of
3:3. We recovered the complex containing fractions by size exclusion chroma-
tography (Superdex 200) and concentrated the proteins to 15 mg/ml in 25 mM
HEPES (pH 7.4) buffer containing 20 mM sodium chloride. Crystals of the
OPG-RANKL complex grew in hanging drops at 20C. Optimum crystal
growth occurred in 100 mM sodium phosphate/citrate buffer (pH 4.1), 14%
polyethylene glycol 8000, and 250 mM sodium chloride. The crystals were
cryoprotected by a short soak in well solution containing 30% ethylene glycol.
Similarly, RANK and RANKLweremixed at amolar ratio of 4.5:3 and incubated
at 4C overnight before crystallization. Hexagonal-rod-shaped crystals
formed in hanging drops at 20C produced by mixing equal volumes of pro-
tein and well buffer containing 2.0 M sodium chloride, 100 mM EDTA, and
100 mM sodium acetate (pH 4.6). The crystals were cryoprotected using
25% xylitol in well solution. In both cases, the crystals were held in a stream
of nitrogen gas (100 K) for data collection.
Structure Determination and Refinement
The OPG-RANKL crystals belong to space group P63 with unit cell dimensions
a = b = 109.6 A˚ and c = 78.7 A˚. The asymmetric unit consists of one monomer
of OPG and one monomer of RANKL. Diffraction data were collected to
2.70 A˚ resolution at the Advanced Light Source Synchrotron (beamline 4.2.2)
using a CCD detector (Noir-1) and processed with HKL2000 (Otwinowski
and Minor, 1997). A combination of molecular replacement using our previ-
ously published RANKL model (Lam et al., 2001) and MAD technique using
labeled RANKL allowed phasing of the structure. The RANK-RANKL crystals
also belong to space group P63, but have slightly larger unit cell dimensions
a and b = 120.6 A˚, c = 94.3 A˚. Complete data to 2.7 A˚ resolution was collected
using a Rigaku rotating anode generator equipped for Cu-Ka radiation with
Osmic confocal mirrors and an R-Axis IV detector. Data sets were processed
with DENZO and SCALEPACK. The RANKL-RANK complex structure was
determined initially by molecular replacement using the RANKL coordinates
as a search probe (Lam et al., 2001). After locating RANKL, a putative RANK
model was fit into the electron density map with COOT (Emsley and Cowtan,
2004). The theoretical RANK coordinates were generated using 3D-PSSM
(Kelley et al., 2000), using a related TNF receptor (p55, Protein Data Bank
1TNR) as the model (Banner et al., 1993). The structure was refined using Phe-
nix (Adams et al., 2010). Repeated iteration between manual rebuilding and
error minimization was applied as guided by R-free. The final refined structures
of both the OPG-RANKL and RANK-RANKL complexes have good crystallo-
graphic R factors and stereochemistry. The refinement statistics are summa-
rized in Table 1. Figures were prepared using PyMOL (Schrodinger, 2012).
Buried surface area was calculated using the PISA server (Krissinel and Hen-
rick, 2007). NCONT (CCP4 Program Suite) (Collaborative Computational
Project, Number 4, 1994) was used to determine ligand-receptor contacts
within 4.0 A˚. HBPLUS (McDonald and Thornton, 1994) was used to assess
neighbor interactions and the geometry of hydrogen bonds. Shape comple-
mentarity was calculated using Sc (Lawrence and Colman, 1993).
Quantitative and Kinetic Binding Measurements
The binding of soluble monomeric OPG and RANK CRD regions to RANKL
was examined using a Biacore T100 surface plasmon resonance-based
instrument. Between 400 and 1,000 response units of murine RANKL (cleaved
and purified to remove the GST-affinity tag) were immobilized to the dextran
matrix of a CM5 sensor chip by amine coupling in 10 mM sodium phosphate
buffer (pH 5.2) at a flow rate of 5 ml/min. The flow cell was activated at 5 ml/min
using a 1:1 mixture of 0.1 M N-hydoxysuccinimide and 0.1 M 3-(N,N-dimethy-
lamino)-propyl-N-ethylcarbondimide. An adjacent flow cell was coupled with
neutravidin to serve as a control for nonspecific binding. The coupling reac-
tion was stopped by injection of 1 M ethanolamine (pH 8.5) for 5 min. Varying
concentrations of monovalent receptor fragment (the N-terminal cytokine-
binding CRDs 1 through 4) of RANK, OPG, or its variants were injected over
the chip at a flow rate of 20 ml/min. The binding buffer consisted of 10 mM
HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, and 0.05% v/v Surfactant P20.
Regeneration was accomplished by passing binding buffer over the sensor
surface until complete dissociation had occurred. For RANK, the sensorgrams1980 Structure 20, 1971–1982, November 7, 2012 ª2012 Elsevier Ltdwere fit to a simple 1:1 reaction model using BIA evaluation software (Biacore,
GE Healthcare). For OPG and its variants, the data were fit using a two-state
reaction model (binding with conformational change), which is consistent
with the required conformational changes observed for bound OPG. The
data fit the two-state reaction model better. For example, for the wild-type
OPG CRD binding data shown in Figure 5A, values of Chi2 were 0.231 for
the two-state model and 8.48 for the 1:1 binding model. In addition, the
curve-fit residuals were always less than 10% for the two-state model, but
ranged as high as 35% for the 1:1 state model.
Osteoclast Formation and Tartrate-Resistant
Acid Phosphatase Staining
Primary bone marrow macrophage cells (BMMs) were obtained by flushing
bone marrow cells from femurs and tibia of 6–8-week-old C57BL/6 mice. After
red blood cell lysis, the cells were resuspended in a-minimum essential
medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS) and cultured in 100 ng/ml M-CSF at 37C for 4 days. Floating cells
and debris were removed by washing with PBS and then the adherent
BMMs lifted with trypsin-EDTA. Cells were plated into 96-well tissue-culture-
treated plates under conditions to support further growth of BMMs (20 ng/ml
M-CSF) or osteoclasts (20 ng/ml M-CSF plus 100 ng/ml RANKL), but with
varying concentrations of monomeric RANK or OPG CRDs 1 through 4. The
medium was changed every 2 days. On day 5, the cells were fixed with
room-temperature paraformaldehyde (4% in PBS) and stained for TRAP
expression using a kit (Sigma-Aldrich). TRAP-positive osteoclasts (R3 nuclei)
were counted using a light microscope.
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